| Name | Title | Contact Details |
|---|
Apervita is the trusted healthcare collaboration platform for quality measurement, clinical intelligence, value optimization and interoperability. We empower payers and providers and other stakeholders to more efficiently and effectively measure clinical and financial performance, improve clinical quality and administer and run analytics on value-based contracts. By providing an independent, secure, trusted platform to perform shared analyses, Apervita uniquely allows stakeholders to gain mutual, continuous clinical and financial insights and integrate those insights in various systems and workflows simultaneously and at scale. Serving more than one in three hospitals in the United States and several nationally recognized health plans, Apervita conducts more than 10 billion value-based computations and insights for our clients every year. Serving more than one in five hospitals in the United States and several nationally recognized health plans, Apervita conducts more than 1 billion value-based computations and insights for our clients every year. Founded in 2012, the company maintains office locations in Chicago and Boston.
Interim Healthcare of Greenville is a Greenville, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Episcopal Health Services (EHS) traces its roots almost 150 years back to the Church Charity Foundation which was founded on February 6, 1851 for aged indigent persons and for the welfare of orphans, half orphans, and other destitute children.
Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.
Intervet/ Schering-Plough Animal Health is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.